Markets:

Overview

News

Currencies

International

Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

64.11 -2.42 (-3.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

7 Biotech Stocks to Put on Your Breakthrough Radar ↗

May 27, 2024

Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.

Via InvestorPlace

Analyst Expectations For Arcellx's Future ↗

May 14, 2024

Via Benzinga

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine ↗

May 09, 2024

These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.

Via InvestorPlace

Peering Into Arcellx's Recent Short Interest ↗

April 15, 2024

Via Benzinga

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

Arcellx Analysts Boost Their Forecasts After Q4 Results ↗

February 29, 2024

Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday.

Via Benzinga

Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know ↗

January 04, 2024

Via Benzinga

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

Decoding Bearish Analog And The Warning Signs You Can't Ignore ↗

February 07, 2024

A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore.

Via Talk Markets

Topics Stocks

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗

January 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

Via InvestorPlace

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗

December 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

Via InvestorPlace

Where Arcellx Stands With Analysts ↗

December 11, 2023

Via Benzinga

Analyst Ratings for Arcellx ↗

June 20, 2023

Via Benzinga

Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 12, 2023

Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.

Via Benzinga

Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say ↗

December 11, 2023

Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or

Via Benzinga

Chart Of The Day: Arcellx - Reimagining Cell Therapy ↗

December 08, 2023

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.

Via Talk Markets

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead ↗

November 15, 2023

The companies will work together on treatments for multiple myeloma and lymphomas.

Via Investor's Business Daily

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 02, 2023

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.

Via Benzinga

Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today? ↗

November 02, 2023

Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refra

Via Benzinga

Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday ↗

November 02, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs ↗

October 02, 2023

CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.

Via InvestorPlace

Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential ↗

August 15, 2023

The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program.

Via Benzinga

FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study ↗

August 15, 2023

The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 14, 2023

Via Benzinga

Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 20, 2023

Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arcellx, Inc. - Common Stock (NQ:ACLX)

Headline News about Arcellx, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today